|Articles|April 12, 2012
J&J hit with $1.2 Billion Penalty in Drug Case
Advertisement
An Arkansas judge slapped Johnson & Johnson and a subsidiary with more than $1.2 billion in penalties on Wednesday for deceptive marketing of the antipsychotic drug Risperdal.
The ruling marks the latest legal headache for J&J over the drug. Johnson & Johnson has faced lawsuits in a total of 11 states in connection with Risperdal.
Read the full story:
Source: CNN Money
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
AI-Supported Mammography Caught More Cancers During Screening
3
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
4
CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment
5
